Boston Scientific Corp Stock Net Asset

BSX Stock

USD 104.92 1.84 1.72%

By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Boston Scientific's long-term financial health and intrinsic value.

Short Long Term Debt Total Total Assets

Build AI portfolio with Boston Stock

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Boston Scientific Corp Company Net Asset Analysis

Boston Scientific's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.

Net Asset

Current Market Value

-

Current Liabilities

More About Net Asset | All Equity Analysis

Current Boston Scientific Net Asset

39.4 B

Most of Boston Scientific's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Boston Scientific Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Boston Net Asset Driver Correlations

Understanding the fundamental principles of building solid financial models for Boston Scientific is extremely important. It helps to project a fair market value of Boston Stock properly, considering its historical fundamentals such as Net Asset. Since Boston Scientific's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Boston Scientific's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Boston Scientific's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Short Term Investments	Common Stock	Long Term Debt	Good Will	Treasury Stock	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.98	0.96	0.61	0.92	0.95	0.76	0.97	0.4	0.56	0.79	0.63	0.85	0.88	-0.74	0.94	-0.38	0.82	0.71	0.87	-0.6	0.68	0.3	0.55	0.88	0.77	0.76
Total Stockholder Equity	0.98		0.91	0.74	0.92	0.91	0.66	0.95	0.35	0.42	0.77	0.51	0.8	0.88	-0.65	0.95	-0.31	0.88	0.75	0.91	-0.51	0.63	0.27	0.57	0.92	0.8	0.82
Net Debt	0.96	0.91		0.57	0.88	0.94	0.76	0.91	0.55	0.58	0.85	0.61	0.82	0.81	-0.74	0.89	-0.45	0.74	0.7	0.8	-0.66	0.74	0.44	0.42	0.85	0.69	0.71
Retained Earnings	0.61	0.74	0.57		0.68	0.49	0.16	0.57	0.24	-0.22	0.61	-0.14	0.46	0.57	-0.21	0.69	-0.15	0.78	0.78	0.75	-0.16	0.43	0.21	0.48	0.84	0.69	0.76
Accounts Payable	0.92	0.92	0.88	0.68		0.91	0.64	0.91	0.42	0.34	0.84	0.52	0.76	0.83	-0.75	0.94	-0.47	0.84	0.72	0.92	-0.68	0.62	0.31	0.54	0.89	0.75	0.79
Net Receivables	0.95	0.91	0.94	0.49	0.91		0.72	0.91	0.54	0.6	0.77	0.7	0.73	0.82	-0.74	0.95	-0.36	0.76	0.54	0.79	-0.69	0.59	0.45	0.34	0.78	0.58	0.74
Total Liab	0.76	0.66	0.76	0.16	0.64	0.72		0.77	0.24	0.84	0.62	0.86	0.91	0.84	-0.79	0.57	-0.52	0.45	0.59	0.65	-0.61	0.65	0.12	0.42	0.65	0.59	0.38
Total Current Assets	0.97	0.95	0.91	0.57	0.91	0.91	0.77		0.35	0.51	0.81	0.64	0.86	0.84	-0.83	0.89	-0.42	0.83	0.72	0.91	-0.66	0.76	0.24	0.67	0.87	0.83	0.75
Short Term Debt	0.4	0.35	0.55	0.24	0.42	0.54	0.24	0.35		0.24	0.66	0.18	0.1	0.27	-0.25	0.45	-0.16	0.21	0.06	0.24	-0.38	0.34	0.98	-0.18	0.31	0.03	0.39
Intangible Assets	0.56	0.42	0.58	-0.22	0.34	0.6	0.84	0.51	0.24		0.3	0.88	0.62	0.58	-0.52	0.37	-0.28	0.11	0.13	0.24	-0.4	0.32	0.17	0.06	0.26	0.18	0.09
Short Term Investments	0.79	0.77	0.85	0.61	0.84	0.77	0.62	0.81	0.66	0.3		0.38	0.69	0.69	-0.69	0.74	-0.6	0.68	0.69	0.8	-0.67	0.8	0.55	0.52	0.81	0.73	0.62
Common Stock	0.63	0.51	0.61	-0.14	0.52	0.7	0.86	0.64	0.18	0.88	0.38		0.68	0.67	-0.73	0.5	-0.43	0.32	0.23	0.45	-0.64	0.45	0.07	0.21	0.37	0.31	0.31
Long Term Debt	0.85	0.8	0.82	0.46	0.76	0.73	0.91	0.86	0.1	0.62	0.69	0.68		0.87	-0.8	0.68	-0.54	0.66	0.85	0.83	-0.59	0.75	-0.03	0.65	0.84	0.83	0.53
Good Will	0.88	0.88	0.81	0.57	0.83	0.82	0.84	0.84	0.27	0.58	0.69	0.67	0.87		-0.65	0.82	-0.33	0.73	0.71	0.86	-0.49	0.57	0.18	0.46	0.86	0.7	0.7
Treasury Stock	-0.74	-0.65	-0.74	-0.21	-0.75	-0.74	-0.79	-0.83	-0.25	-0.52	-0.69	-0.73	-0.8	-0.65		-0.64	0.56	-0.59	-0.59	-0.76	0.84	-0.72	-0.08	-0.58	-0.66	-0.7	-0.46
Property Plant Equipment	0.94	0.95	0.89	0.69	0.94	0.95	0.57	0.89	0.45	0.37	0.74	0.5	0.68	0.82	-0.64		-0.24	0.9	0.62	0.87	-0.57	0.54	0.38	0.39	0.86	0.66	0.86
Current Deferred Revenue	-0.38	-0.31	-0.45	-0.15	-0.47	-0.36	-0.52	-0.42	-0.16	-0.28	-0.6	-0.43	-0.54	-0.33	0.56	-0.24		-0.25	-0.47	-0.41	0.69	-0.61	-0.06	-0.41	-0.4	-0.48	-0.12
Net Tangible Assets	0.82	0.88	0.74	0.78	0.84	0.76	0.45	0.83	0.21	0.11	0.68	0.32	0.66	0.73	-0.59	0.9	-0.25		0.73	0.91	-0.48	0.62	0.14	0.54	0.87	0.8	0.85
Long Term Debt Total	0.71	0.75	0.7	0.78	0.72	0.54	0.59	0.72	0.06	0.13	0.69	0.23	0.85	0.71	-0.59	0.62	-0.47	0.73		0.85	-0.41	0.74	-0.05	0.7	0.91	0.89	0.62
Capital Surpluse	0.87	0.91	0.8	0.75	0.92	0.79	0.65	0.91	0.24	0.24	0.8	0.45	0.83	0.86	-0.76	0.87	-0.41	0.91	0.85		-0.61	0.71	0.13	0.71	0.95	0.9	0.82
Deferred Long Term Liab	-0.6	-0.51	-0.66	-0.16	-0.68	-0.69	-0.61	-0.66	-0.38	-0.4	-0.67	-0.64	-0.59	-0.49	0.84	-0.57	0.69	-0.48	-0.41	-0.61		-0.63	-0.26	-0.34	-0.51	-0.47	-0.41
Long Term Investments	0.68	0.63	0.74	0.43	0.62	0.59	0.65	0.76	0.34	0.32	0.8	0.45	0.75	0.57	-0.72	0.54	-0.61	0.62	0.74	0.71	-0.63		0.21	0.61	0.69	0.76	0.52
Short Long Term Debt	0.3	0.27	0.44	0.21	0.31	0.45	0.12	0.24	0.98	0.17	0.55	0.07	-0.03	0.18	-0.08	0.38	-0.06	0.14	-0.05	0.13	-0.26	0.21		-0.27	0.22	-0.08	0.34
Cash And Equivalents	0.55	0.57	0.42	0.48	0.54	0.34	0.42	0.67	-0.18	0.06	0.52	0.21	0.65	0.46	-0.58	0.39	-0.41	0.54	0.7	0.71	-0.34	0.61	-0.27		0.62	0.89	0.4
Net Invested Capital	0.88	0.92	0.85	0.84	0.89	0.78	0.65	0.87	0.31	0.26	0.81	0.37	0.84	0.86	-0.66	0.86	-0.4	0.87	0.91	0.95	-0.51	0.69	0.22	0.62		0.87	0.82
Net Working Capital	0.77	0.8	0.69	0.69	0.75	0.58	0.59	0.83	0.03	0.18	0.73	0.31	0.83	0.7	-0.7	0.66	-0.48	0.8	0.89	0.9	-0.47	0.76	-0.08	0.89	0.87		0.59
Capital Stock	0.76	0.82	0.71	0.76	0.79	0.74	0.38	0.75	0.39	0.09	0.62	0.31	0.53	0.7	-0.46	0.86	-0.12	0.85	0.62	0.82	-0.41	0.52	0.34	0.4	0.82	0.59

Click cells to compare fundamentals

Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.

Competition

Predict Boston Scientific

Boston Total Assets

Total Assets

41.36 Billion

At this time, Boston Scientific's Total Assets are fairly stable compared to the past year.

Based on the recorded statements, Boston Scientific Corp has a Net Asset of 39.4 B. This is much higher than that of the Health Care Equipment & Supplies sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.

Boston Net Asset Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Boston Scientific's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Boston Scientific could also be used in its relative valuation, which is a method of valuing Boston Scientific by comparing valuation metrics of similar companies.

Boston Scientific is currently under evaluation in net asset category among its peers.

Boston Scientific ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Boston Scientific's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Boston Scientific's managers, analysts, and investors.

Environmental

Governance

Social

Boston Scientific Institutional Holders

Institutional Holdings refers to the ownership stake in Boston Scientific that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Boston Scientific's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Boston Scientific's value.

		Shares
Norges Bank	2024-12-31	19.7 M
Morgan Stanley - Brokerage Accounts	2025-03-31	19 M
Dz Bank Ag Deutsche Zentral-genossenschaftsbank Frankfurt Am Main	2025-03-31	17.7 M
Amvescap Plc.	2025-03-31	16.6 M
Massachusetts Financial Services Company	2025-03-31	16.5 M
Northern Trust Corp	2025-03-31	14.3 M
Hhg Plc	2025-03-31	14 M
Goldman Sachs Group Inc	2025-03-31	13.9 M
Amundi	2025-03-31	12.3 M
Blackrock Inc	2025-03-31	141.7 M
Vanguard Group Inc	2025-03-31	134.6 M

Boston Fundamentals

	Return On Equity	0.095
	Return On Asset	0.0528
	Profit Margin	0.14 %
	Operating Margin	0.20 %
	Current Valuation	166.21 B
	Shares Outstanding	1.48 B
	Shares Owned By Insiders	0.18 %
	Shares Owned By Institutions	93.63 %
	Number Of Shares Shorted	19.57 M
	Price To Earning	107.05 X
	Price To Book	6.99 X
	Price To Sales	8.39 X
	Revenue	16.75 B
	Gross Profit	12.7 B
	EBITDA	3.86 B
	Net Income	1.85 B
	Cash And Equivalents	414 M
	Cash Per Share	0.24 X
	Total Debt	11.15 B
	Debt To Equity	0.51 %
	Current Ratio	1.45 X
	Book Value Per Share	15.02 X
	Cash Flow From Operations	3.44 B
	Short Ratio	2.65 X
	Earnings Per Share	1.68 X
	Price To Earnings To Growth	1.84 X
	Target Price	124.14
	Number Of Employees	53 K
	Beta	0.68
	Market Capitalization	155.22 B
	Total Asset	39.4 B
	Retained Earnings	2.67 B
	Working Capital	521 M
	Current Asset	1.21 B
	Current Liabilities	923 M
	Net Asset	39.4 B

About Boston Scientific Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Boston Scientific Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Boston Scientific using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Boston Scientific Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

USOI	Credit Suisse X Links
ULTY	Tidal Trust II
CONY	YieldMax N Option

Additional Tools for Boston Stock Analysis

When running Boston Scientific's price analysis, check to measure Boston Scientific's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Boston Scientific is operating at the current time. Most of Boston Scientific's value examination focuses on studying past and present price action to predict the probability of Boston Scientific's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Boston Scientific's price. Additionally, you may evaluate how the addition of Boston Scientific to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC